Tricyclic aromatic compounds
AssigneeBurroughs Wellcome Co.
InventorsO. William Lever, Jr., Harry J. Leighton
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula I ##STR1## or a salt, ester or amide thereof; wherein R.sup.1 is --CH.sub.2 --CH.sub.2 --, CH.sub.2 --O-- or --O--CH.sub.2 --; R.sup.2 and R.sup.3 are the same or different and are each hydrogen, C.sub.1-4 alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members; R.sup.4 is a single bond or a C.sub.1-7 bivalent aliphatic hydrocarbon group and may be joined to the aromatic ring system at the 2,3,8 or 9 positions; n is 0 to 3, and their use as antihistamine and antiasthma agents.
Claims12
A method of treating allergy in a mammal which comprises administering to a mammal in need thereof an effective allergy treatment amount of a compound of formula (I) ##STR10## or a pharmacologically and pharmaceutically acceptable salt thereof;
- wherein R.sup.1 is --CH.sub.2 --O--, R.sup.2 and R.sup.3 are the same or different and are each hydrogen or C.sub.1-4 alkyl, R.sup.4 is a C.sub.1-2 bivalent hydrocarbon group and is joined to the aromatic ring system at the 2 position and n is 2.
A method of treating asthma in a mammal which comprises administering to a mammal in need thereof an effective asthma treatment amount of a compound of formula (I) ##STR11## or a pharmacologically and pharmaceutically acceptable salt thereof;
- wherein R.sup.1 is --CH.sub.2 --O--, R.sup.2 and R.sup.3 are the same or different and are each hydrogen or C.sub.1-4 alkyl, R.sup.4 is a C.sub.1-2 bivalent hydrocarbon group and is joined to the aromatic ring system at the 2 position and n is 2.
A pharmaceutical formulation for use in treating allergy or asthma comprising an effective allergy or asthma treatment amount of:
- ##STR12## or a pharmacologically and pharmaceutically acceptable salt thereof;
- wherein R.sup.1 is --CH.sub.2 --O--, R.sup.2 and R.sup.3 are the same or different and are each hydrogen or C.sub.1-4 alkyl, R.sup.4 is a C.sub.1-2 bivalent hydrocarbon group and is joined to the aromatic ring system at the 2 position and n is 2 and a pharmaceutically acceptable carrier therefore.
Dependencies are inferred from the claim text.